Biological Therapy for Multiple Myeloma
作者： Camilo Ayala-Breton , Stephen J. Russell , Kah-Whye Peng
DOI: 10.1007/978-1-4614-8520-9_13
关键词:
摘要: The National Cancer Institute defines biological therapy as: “A form of treatment that implies the administration substances which produce a reaction in organism thus enhancing or restoring host immune response, modifying behavior cancer cells, blocking pathways cell neoplastic transformation and tumor ability to metastasize, facilitating repair cells damaged by aggressive forms treatment. It includes use sera, antitoxins, vaccines, genes, tissues, organs.” In this chapter we will highlight different therapies have been recently used against multiple myeloma (MM).
elsevier.com
springer.com
sci-hub.st 参考文章(152)
ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna, DR Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood. ,vol. 83, pp. 435- 445 ,(1994) , 10.1182/BLOOD.V83.2.435.435
Angela Dispenzieri, Evanthia Galanis, Pavlos Msaouel, Pavlos Msaouel, Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Current Opinion in Molecular Therapeutics. ,vol. 11, pp. 43- 53 ,(2009)
A Neri, L Baldini, D Trecca, L Cro, E Polli, AT Maiolo, p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy Blood. ,vol. 81, pp. 128- 135 ,(1993) , 10.1182/BLOOD.V81.1.128.128
H Harada, MM Kawano, N Huang, Y Harada, K Iwato, O Tanabe, H Tanaka, A Sakai, H Asaoku, A Kuramoto, Phenotypic difference of normal plasma cells from mature myeloma cells Blood. ,vol. 81, pp. 2658- 2663 ,(1993) , 10.1182/BLOOD.V81.10.2658.BLOODJOURNAL81102658
T Goto, SJ Kennel, M Abe, M Takishita, M Kosaka, A Solomon, S Saito, A novel membrane antigen selectively expressed on terminally differentiated human B cells Blood. ,vol. 84, pp. 1922- 1930 ,(1994) , 10.1182/BLOOD.V84.6.1922.1922
Ellen S. Vitetta, James A. Richardson, Yi-Wu Huang, Anti-CD54 (ICAM-1) Has Antitumor Activity in SCID Mice with Human Myeloma Cells Cancer Research. ,vol. 55, pp. 610- 616 ,(1995)
Gerrard Teoh, Ling Chen, Mitsuyoshi Urashima, Yu-Tzu Tai, Leo A Celi, Dongshu Chen, Dharminder Chauhan, Atsushi Ogata, Robert W Finberg, Iain J Webb, Donald W Kufe, Kenneth C Anderson, None, Adenovirus Vector-Based Purging of Multiple Myeloma Cells Blood. ,vol. 92, pp. 4591- 4601 ,(1998) , 10.1182/BLOOD.V92.12.4591
D R Shafren, D J Dorahy, R A Ingham, G F Burns, R D Barry, Coxsackievirus A21 Binds to Decay-Accelerating Factor but Requires Intercellular Adhesion Molecule 1 for Cell Entry Journal of Virology. ,vol. 71, pp. 4736- 4743 ,(1997) , 10.1128/JVI.71.6.4736-4743.1997
Hironobu Tatsuo, Nobuyuki Ono, Kotaro Tanaka, Yusuke Yanagi, SLAM (CDw150) is a cellular receptor for measles virus. Nature. ,vol. 406, pp. 893- 897 ,(2000) , 10.1038/35022579
Lothar Kanz, Theodora Schammann, Frank Grünebach, Peter Brossart, Stefan Wirths, Wolfram Brugger, Hans-Jörg Bühring, Anya Schneider, Patricia Dill, The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Research. ,vol. 61, pp. 6846- 6850 ,(2001)